<DOC>
	<DOCNO>NCT01184820</DOCNO>
	<brief_summary>The purpose study describe pharmacokinetics ( PK ) BAY94-9027 ( test drug ) . Pharmacokinetics mean measure well study drug corrects factor VIII level blood long take level fall back baseline level . The study also design determine pharmacokinetics BAY94-9027 change follow repeat dose 8 week , determine BAY94-9027 safe , tolerable , effective treatment severe hemophilia A define appropriate dose BAY94-9027 . Two dose BAY94-9027 study . The first 8 subject enrol study ( cohort 1 ) receive low dose ( 25 IU/kg ) treat 2 day week 8 week ( total 16 dos ) . The second 8 subject ( cohort 2 ) receive high dose treat 1 day week 8 week ( total 8 dos ) . All subject receive single dose rFVIII ( Bayer Kogenate FS ) determine PK measure blood level 2 day start study drug BAY94-9027 . Factor VIII blood level BAY94-9027 measure 7 day first last dose see describe PK . Safety &amp; tolerability assessment include vital sign , coagulation hematological parameter , clinical chemistry , measurement FVIII inhibitor polyethylene glycol ( PEG ) antibodies do course study .</brief_summary>
	<brief_title>Trial Evaluate Pharmacokinetics Safety Profile BAY94-9027 Following Single Multiple Dose Administration</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male subject severe hemophilia A ( document plasma baseline Factor VIII level &lt; 1 % ) &gt; /= 18 &lt; /= 65 year age Previously treat Factor VIII concentrate ( ) minimum 150 exposure day ( supported subject 's medical history ) Immunocompetent CD4+ lymphocyte count &gt; 400/mm³ Signed inform consent subject Documented history inhibitor Factor VIII titer &gt; /= 0.6 BU ( Biological Unit ) , Nijmegen modify assay . However , subject maximum historical titer &lt; /= 1.0 BU classical Bethesda assay single measurement least 3 subsequent successive negative result ( &lt; 0.6 BU ) thereafter eligible . Unable stop Factor VIII treatment complete minimum 72 hour washout Current evidence inhibitor Factor VIII titer &gt; /= 0.6 BU , measure time screen Abnormal renal function ( serum creatinine &gt; 1.5 time upper limit normal range ) Total bilirubin &gt; 1.5 time upper limit normal range Active hepatic disease ( alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) level &gt; 2 time upper limit normal range ) Any concomitant coagulation disorder hemophilia A ( include lupus anticoagulant ) Platelet count &lt; 100,000/mm³ Within last 3 month prior study entry study treat immunomodulating drug antiretroviral chemotherapy ( e.g. , interferon , steroid , rituximab , etc ) Any subject require major surgery study period . Minor procedure may approve discussed advance medical expert .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
</DOC>